Disc Medicine, Inc. Net Change in Cash
Disc Medicine, Inc. (IRON) reported Net Change in Cash of $7.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-30
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$2.23M.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$69.76M.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$17.77M, a 142.49% decline year-over-year.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $41.81M, a 204.17% increase year-over-year.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$101.28M.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$167.94M, a 201.28% decline from fiscal 2023.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $165.83M, a 55.60% increase from fiscal 2022.
- Disc Medicine, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $106.58M, a 70.99% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.53M 10-Q · filed 2026-07-30 | |||||||
| 2026-03-31 | -$2.23M 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | -$101.28M 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | -$51.77M 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | -$65.09M 10-Q · filed 2026-07-30 | |||||||
| 2025-03-31 | -$69.76M 10-Q · filed 2026-05-05 | |||||||
| 2024-12-31 | -$167.94M 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | -$167.74M 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | -$79.72M 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | -$17.77M 10-Q · filed 2025-05-07 | |||||||
| 2023-12-31 | $165.83M 10-K · filed 2026-02-26 | |||||||
| 2023-09-30 | $175.87M 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | $182.93M 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | $41.81M 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $106.58M 10-K · filed 2024-03-21 | |||||||
| 2022-09-30 | -$32.56M 10-Q · filed 2023-11-09 | -$35.21M 10-Q · filed 2022-11-10 | ||||||
| 2022-06-30 | -$22.87M 10-Q · filed 2023-08-11 | -$28.29M 10-Q · filed 2022-08-11 | ||||||
| 2022-03-31 | $13.75M 10-Q · filed 2023-05-15 | -$17.56M 10-Q · filed 2022-05-06 | ||||||
| 2021-12-31 | $62.33M 10-K · filed 2023-03-31 | $132.12M 10-K · filed 2022-03-10 | ||||||
| 2021-09-30 | $145.57M 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | $162.97M 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | $180.48M 10-Q · filed 2022-05-06 | |||||||
| 2020-12-31 | $1.21M 10-K · filed 2021-03-29 | $1.52M 10-K · filed 2022-03-10 | ||||||
| 2020-09-30 | $1.44M 10-Q · filed 2020-11-12 | $10.23M 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $3.19M 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | $10.21M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |